Industry Connect with target validation and drug discovery funding available from Pfizer

Pfizer's Centres for Therapeutic Innovation (CTI), is a unique joint drug discovery model focused on collaborating with leading academic medical centres to translate and transform concepts into breakthroughs that change patients' lives.

The CTI 2020 Call for Proposals (CFP) is focused on identifying novel therapeutic opportunities in the areas outlined below with application in Pfizer’s core research focus areas: oncology, inflammation & immunology, internal medicine and rare diseases.

CTI collaborations include funding, hands-on collaboration, access to scientific/technological expertise and infrastructure, potential for in-licensing by Pfizer, publishing rights.

Pfizer CTI and UniQuest invite you to submit a non-confidential 2-3 page pre-proposal.

Core research focus areas

Oncology

Inflammation & immunology

Internal medicine

Rare diseases

Areas of Interest and Targets/Pathways of Focus

DNA Damage Response and Replicative Stress

Repeat Expansion Diseases

Cellular Senescence

Tissue-Immune System Crosstalk

Download Pfizer CTI flyer to check if your research fits with their specific drug targets and pathways of strategic focus

Next steps

Download Pre-Proposal Application Form and discuss with UniQuest

Complete Pre-Proposal adhering to the word limits and advice regarding tables and graphs

Non confidential pre-proposals must not exceed three pages

Pre-proposals submitted will be reviewed on a rolling basis

Pfizer Centres for Therapeutic Innovation (CTI)

Call for Proposals for Therapeutic Targets now open

To check the areas of interest and targets/pathways of focus, download the Pfizer CTI flyer.
Interested researchers should reach out to their UniQuest representative and download the three-page non-confidential Pre-Proposal Application Form.

Applications close 21 September 2020

Forward completed Pre-Proposal Application Forms to pfizer@uniquest.com.au by 21 September 2020.

Pre-Proposals submitted will be reviewed on a rolling basis.

Contact us

Contact us for more information about this and other Industry Connect events.

Contact us